Enzalutamide (n = 14) n (%) | Abiraterone (n = 14) n (%) | |
---|---|---|
Any PSA decline | 13 (93) | 5 (36) |
PSA decline ≥30 % | 9 (64) | 1 (7) |
PSA decline ≥50 % | 7 (50) | 1 (7) |
Median PFS, mo (95 % CI) | 5.0 (3.7–6.4) | 3.4 (0.8–6.0) |
Type of progression | ||
PSA PD | 10 (72) | 8 (57) |
Radiographic PD | 3 (21) | 5 (36) |
Clinical PD | 1 (7) | 1 (7) |